Hassan Mohamed Ismail, Laz Nabila Ibrahim, Madney Yasmin M, Abdelrahim Mohamed E A, Harb Hadeer S
Department of Pharmacy Practice, Faculty of Pharmacy, Sinai University-Al Arish Campus, Al Arish, North Sinai, 45511, Egypt.
Department of Chest Diseases, Faculty of Medicine, Beni-Suef University, Beni-Suef, 62511, Egypt.
Clin Pharmacokinet. 2025 Aug 29. doi: 10.1007/s40262-025-01560-x.
BACKGROUND: Suboptimal peak inspiratory flow rates (PIFR) are common in patients with chronic obstructive pulmonary disease (COPD), hindering effective medication dispersion and aerosol delivery. This study aimed to assess whether administering a preliminary bronchodilator dose via a pressurized metered-dose inhaler (pMDI) improves aerosol drug delivery via dry powder inhaler (DPI) in patients with COPD with suboptimal PIFR (< 60 L/min), compared with those with optimal PIFR (≥ 60 L/min). METHODS: Overall, 24 patients with COPD were evaluated. PIFR was measured using the In-Check Dial G16, dividing patients into optimal and suboptimal groups. All patients received a 200 µg dose of salbutamol via Diskus DPI. Patients with COPD with suboptimal PIFR received two puffs (100 µg each) preceded by a preliminary salbutamol dose administered via pMDI. Urine salbutamol levels (USAL30) and salbutamol that was eluted from filters (SALF) were measured after 30 min to assess lung deposition through high-performance liquid chromatography (HPLC). RESULTS: Patients with COPD with suboptimal PIFR without a preliminary dose had significantly lower USAL30 than the optimal group (4.99% versus 6.18%, p = 0.013). A preliminary dose improved USAL30 in the suboptimal group but did not reach statistical significance (5.45% versus 4.99%, p = 0.071). CONCLUSIONS: A significant difference in aerosol drug delivery was observed between optimal and suboptimal groups without a preliminary dose, suggesting that inhaler selection in patients with COPD may need to be individualized on the basis of inspiratory flow capability. Administering a preliminary dose of pMDI before using a DPI minimally affects the suboptimal inhalation through DPI.
背景:慢性阻塞性肺疾病(COPD)患者中吸气峰流速(PIFR)欠佳很常见,这会阻碍有效药物弥散和气溶胶递送。本研究旨在评估对于PIFR欠佳(<60 L/分钟)的COPD患者,与PIFR正常(≥60 L/分钟)的患者相比,通过压力定量吸入器(pMDI)给予初始支气管扩张剂剂量是否能改善干粉吸入器(DPI)的气溶胶药物递送。 方法:总共评估了24例COPD患者。使用In-Check Dial G16测量PIFR,将患者分为正常组和欠佳组。所有患者通过Diskus DPI接受200μg剂量的沙丁胺醇。PIFR欠佳的COPD患者在通过pMDI给予初始沙丁胺醇剂量后再吸入两喷(每次100μg)。30分钟后测量尿沙丁胺醇水平(USAL30)和从滤器洗脱的沙丁胺醇(SALF),通过高效液相色谱法(HPLC)评估肺部沉积情况。 结果:未给予初始剂量的PIFR欠佳的COPD患者的USAL30显著低于正常组(4.99%对6.18%,p = 0.013)。初始剂量改善了欠佳组的USAL30,但未达到统计学意义(5.45%对4.99%,p = 0.071)。 结论:在未给予初始剂量的情况下,正常组和欠佳组之间观察到气溶胶药物递送存在显著差异,这表明COPD患者的吸入器选择可能需要根据吸气流量能力进行个体化。在使用DPI之前给予pMDI初始剂量对通过DPI的欠佳吸入影响最小。
J Aerosol Med Pulm Drug Deliv. 2024-12
Cochrane Database Syst Rev. 2012-7-11
Cochrane Database Syst Rev. 2014-7-21
Respir Care. 2024-11-18
Biol Sex Differ. 2024-4-21
Lancet Respir Med. 2022-2
Int J Clin Pract. 2021-6